By Professor Kerry-Anne Rye

Journal articles

Gierasch LM; Davidson NO; Rye KA; Burlingame AL, 2019, 'For the sake of science', Journal of Lipid Research, 60, pp. 719 - 720, http://dx.doi.org/10.1194/jlr.E093245

Yuan D; Wu BJ; Henry A; Rye KA; Ong KL, 2019, 'Role of fibroblast growth factor 21 in gestational diabetes mellitus: A mini-review', Clinical Endocrinology, 90, pp. 47 - 55, http://dx.doi.org/10.1111/cen.13881

Kim WS; He Y; Phan K; Ahmed RM; Rye KA; Piguet O; Hodges JR; Halliday GM, 2018, 'Altered high density lipoprotein composition in behavioral variant frontotemporal dementia', Frontiers in Neuroscience, 12, http://dx.doi.org/10.3389/fnins.2018.00847

Barter PJ; Cochran BJ; Rye KA, 2018, 'CETP inhibition, statins and diabetes', Atherosclerosis, 278, pp. 143 - 146, http://dx.doi.org/10.1016/j.atherosclerosis.2018.09.033

Robinson JG; Williams KJ; Gidding S; Boršen J; Tabas I; Fisher EA; Packard C; Pencina M; Fayad ZA; Mani V; Rye KA; Nordestgaard BG; Tybjærg-Hansen A; Douglas PS; Nicholls SJ; Pagidipati N; Sniderman A, 2018, 'Eradicating the burden of atherosclerotic cardiovascular disease by lowering apolipoprotein b lipoproteins earlier in life', Journal of the American Heart Association, 7, http://dx.doi.org/10.1161/JAHA.118.009778

Wewege MA; Thom JM; Rye KA; Parmenter BJ, 2018, 'Aerobic, resistance or combined training: A systematic review and meta-analysis of exercise to reduce cardiovascular risk in adults with metabolic syndrome', Atherosclerosis, 274, pp. 162 - 171, http://dx.doi.org/10.1016/j.atherosclerosis.2018.05.002

Barter PJ; Rye KA, 2018, 'Cholesteryl Ester Transfer Protein Inhibitors as Agents to Reduce Coronary Heart Disease Risk', Cardiology Clinics, 36, pp. 299 - 310, http://dx.doi.org/10.1016/j.ccl.2017.12.011

Cochran BJ; Pinheiro D; Prendecki M; Jones B; Cegla J; Lee V; Barter PJ; Murphy AJ; Rye K-A; Woollard KJ, 2018, 'Pro-atherosclerotic Low-density Neutrophils Are Present in Hypercholesterolemia', ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 38, http://dx.doi.org/10.1161/atvb.38.suppl_1.609

Ong KL; Morris MJ; McClelland RL; Hughes TM; Maniam J; Fitzpatrick AL; Martin SS; Luchsinger JA; Rapp SR; Hayden KM; Sandfort V; Allison MA; Rye KA, 2018, 'Relationship of Lipids and Lipid-Lowering Medications with Cognitive Function', American Journal of Epidemiology, 187, pp. 767 - 776, http://dx.doi.org/10.1093/aje/kwx329

Aleidi SM; Yang A; Sharpe LJ; Rao G; Cochran BJ; Rye KA; Kockx M; Brown AJ; Gelissen IC, 2018, 'The E3 ubiquitin ligase, HECTD1, is involved in ABCA1-mediated cholesterol export from macrophages', Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, 1863, pp. 359 - 368, http://dx.doi.org/10.1016/j.bbalip.2017.12.011

Choteau SA; Cuesta Torres LF; Barraclough JY; Elder AMM; Martínez GJ; Chen Fan WY; Shrestha S; Ong KL; Barter PJ; Celermajer DS; Rye KA; Patel S; Tabet F, 2018, 'Transcoronary gradients of HDL-associated MicroRNAs in unstable coronary artery disease', International Journal of Cardiology, 253, pp. 138 - 144, http://dx.doi.org/10.1016/j.ijcard.2017.09.190

Hui TH; McClelland RL; Allison MA; Rodriguez CJ; Kronmal RA; Heckbert SR; Michos ED; Barter PJ; Rye KA; Ong KL, 2018, 'The relationship of circulating fibroblast growth factor 21 levels with incident atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis', Atherosclerosis, 269, pp. 86 - 91, http://dx.doi.org/10.1016/j.atherosclerosis.2017.12.026

Iborra RT; Machado-Lima A; Okuda LS; Pinto PR; Nakandakare ER; Machado UF; Correa-Giannella ML; Pickford R; Woods T; Brimble MA; Rye KA; Lu R; Yokoyama S; Passarelli M, 2018, 'AGE-albumin enhances ABCA1 degradation by ubiquitin-proteasome and lysosomal pathways in macrophages', Journal of Diabetes and its Complications, 32, pp. 1 - 10, http://dx.doi.org/10.1016/j.jdiacomp.2017.09.012

Shrestha S; Wu BJ; Guiney L; Barter PJ; Rye KA, 2018, 'Cholesteryl ester transfer protein and its inhibitors', Journal of Lipid Research, 59, pp. 772 - 783, http://dx.doi.org/10.1194/jlr.R082735

Arsenault BJ; Petrides F; Tabet F; Bao W; Hovingh GK; Boekholdt SM; Ramin-Mangata S; Meilhac O; DeMicco D; Rye KA; Waters DD; Kastelein JJP; Barter P; Lambert G, 2018, 'Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk', Journal of Clinical Lipidology, 12, pp. 130 - 136, http://dx.doi.org/10.1016/j.jacl.2017.10.001

Rosenson RS; Brewer HB; Barter PJ; Björkegren JLM; Chapman MJ; Gaudet D; Kim DS; Niesor E; Rye KA; Sacks FM; Tardif JC; Hegele RA, 2018, 'HDL and atherosclerotic cardiovascular disease: Genetic insights into complex biology', Nature Reviews Cardiology, 15, pp. 9 - 19, http://dx.doi.org/10.1038/nrcardio.2017.115

Ong KL; Waters DD; Fayyad R; Vogt L; Melamed S; DeMicco DA; Rye KA; Barter PJ, 2018, 'Relationship of high-density lipoprotein cholesterol with renal function in patients treated with atorvastatin', Journal of the American Heart Association, 7, pp. e007387, http://dx.doi.org/10.1161/JAHA.117.007387

Perségol L; Darabi M; Dauteuille C; Lhomme M; Chantepie S; Rye KA; Therond P; Chapman MJ; Salvayre R; Nègre-Salvayre A; Lesnik P; Monier S; Kontush A, 2018, 'Small dense HDLs display potent vasorelaxing activity, reflecting their elevated content of sphingosine-1-phosphate', Journal of Lipid Research, 59, pp. 25 - 34, http://dx.doi.org/10.1194/jlr.M076927

Shimabukuro Okuda L; Tallada Iborra R; Ramos Pinto P; Patel M; Fabres Machado U; Rye KA; Passarelli M, 2018, 'Advanced glycated apoaiv is less efficient in reducing inflammation in macrophages and unable to prevent the reduction in ABCA1 and ABCG1 Mrna induced by LPS', Atherosclerosis, 275, pp. e167 - e167, http://dx.doi.org/10.1016/j.atherosclerosis.2018.06.503

Zhang M; Lei D; Peng B; Yang M; Zhang L; Charles MA; Rye KA; Krauss RM; Johns DG; Ren G, 2017, 'Assessing the mechanisms of cholesteryl ester transfer protein inhibitors', Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, 1862, pp. 1606 - 1617, http://dx.doi.org/10.1016/j.bbalip.2017.09.004

Chung RWS; Wang Z; Bursill CA; Wu BJ; Barter PJ; Rye KA; Wu B, 2017, 'Effect of long-term dietary sphingomyelin supplementation on atherosclerosis in mice', PLoS ONE, 12, pp. e0189523, http://dx.doi.org/10.1371/journal.pone.0189523

da Silva KS; Pinto PR; Fabre NT; Gomes DJ; Thieme K; Okuda LS; Iborra RT; Freitas VG; Shimizu MHM; Teodoro WR; Marie SKN; Woods T; Brimble MA; Pickford R; Rye KA; Okamoto M; Catanozi S; Correa-Giannela ML; Machado UF; Passarelli M, 2017, 'N-acetylcysteine counteracts adipose tissue macrophage infiltration and insulin resistance elicited by advanced glycated albumin in healthy rats', Frontiers in Physiology, 8, pp. 723, http://dx.doi.org/10.3389/fphys.2017.00723

Barter PJ; Rye KA, 2017, 'HDL cholesterol concentration or HDL function: Which matters?', European Heart Journal, 38, pp. 2487 - 2489, http://dx.doi.org/10.1093/eurheartj/ehx274

Ong KL; O'Connell R; Januszewski AS; Jenkins AJ; Xu A; Sullivan DR; Barter PJ; Scott RS; Taskinen MR; Waldman B; Colman PG; Best JD; Simes JR; Rye KA; Keech AC, 2017, 'Baseline circulating FGF21 concentrations and increase after fenofibrate treatment predict more rapid glycemic progression in type 2 diabetes: Results from the FIELD study', Clinical Chemistry, 63, pp. 1261 - 1270, http://dx.doi.org/10.1373/clinchem.2016.270876

Cochran BJ; Ryder W; parmar A; Meikle S; Barter P; Rye K, 2017, 'Determining Glucose Metabolism Kinetics Using 18F-FDG Micro-PET/CT', Journal of Visualized Experiments, http://dx.doi.org/10.3791/55184

Pandzic E; Gelissen IC; Whan R; Barter PJ; Sviridov D; Gaus K; Rye KA; Cochran BJ, 2017, 'The ATP binding cassette transporter, ABCG1, localizes to cortical actin filaments', Scientific Reports, 7, http://dx.doi.org/10.1038/srep42025

Cochran BJ; Hou L; Manavalan APC; Moore BM; Tabet F; Sultana A; Torres LC; Tang S; Shrestha S; Senanayake P; Patel M; Ryder WJ; Bongers A; Maraninchi M; Wasinger VC; Westerterp M; Tall AR; Barter PJ; Rye K-A, 2017, 'Impact of Perturbed Pancreatic beta-Cell Cholesterol Homeostasis on Adipose Tissue and Skeletal Muscle Metabolism (vol 65, pg 3610, 2016)', DIABETES, 66, pp. 560 - 560, http://dx.doi.org/10.2337/db17-er02b

Kokkinos J; Tang S; Rye KA; Ong KL, 2017, 'The role of fibroblast growth factor 21 in atherosclerosis', Atherosclerosis, 257, pp. 259 - 265, http://dx.doi.org/10.1016/j.atherosclerosis.2016.11.033

van der Vorst EPC; Theodorou K; Wu Y; Hoeksema MA; Goossens P; Bursill CA; Aliyev T; Huitema LFA; Tas SW; Wolfs IMJ; Kuijpers MJE; Gijbels MJ; Schalkwijk CG; Koonen DPY; Abdollahi-Roodsaz S; McDaniels K; Wang CC; Leitges M; Lawrence T; Plat J; Van Eck M; Rye KA; Touqui L; de Winther MPJ; Biessen EAL; Donners MMPC, 2017, 'High-Density Lipoproteins Exert Pro-inflammatory Effects on Macrophages via Passive Cholesterol Depletion and PKC-NF-κB/STAT1-IRF1 Signaling', Cell Metabolism, 25, pp. 197 - 207, http://dx.doi.org/10.1016/j.cmet.2016.10.013

Melchior JT; Walker RG; Cooke AL; Morris J; Castleberry M; Thompson TB; Jones MK; Song HD; Rye KA; Oda MN; Sorci-Thomas MG; Thomas MJ; Heinecke JW; Mei X; Atkinson D; Segrest JP; Lund-Katz S; Phillips MC; Davidson WS, 2017, 'A consensus model of human apolipoprotein A-I in its monomeric and lipid-free state', Nature Structural and Molecular Biology, 24, pp. 1093 - 1099, http://dx.doi.org/10.1038/nsmb.3501

Wu BJ; Li Y; Ong KL; Sun Y; Shrestha S; Hou L; Johns D; Barter PJ; Rye KA, 2017, 'Reduction of in-stent restenosis by cholesteryl ester transfer protein inhibition', Arteriosclerosis, Thrombosis, and Vascular Biology, 37, pp. 2333 - 2341, http://dx.doi.org/10.1161/ATVBAHA.117.310051

Charlton F; Bobek G; Stait-Gardner T; Price WS; Colafella KMM; Xu B; Makris A; Rye KA; Hennessy A, 2017, 'The protective effect of apolipoprotein in models of trophoblast invasion and preeclampsia', American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 312, pp. R40 - R48, http://dx.doi.org/10.1152/ajpregu.00331.2016

Stanton K; Kienzle V; Dinnes D; Jessup W; Kritharides L; Rye K; Celermajer D, 2017, 'Exercise During Military Training and Substantial Improvements in Cardiometabolic Health–The NSW Healthy Military Recruits Cardiometabolism (NHMRC) Study', Heart, Lung and Circulation, 26, pp. S115 - S116, http://dx.doi.org/10.1016/j.hlc.2017.06.167

Van Der Vorst E; Theodorou K; Wu Y; Hoeksema M; Goossens P; Bursill C; Aliyev T; Tas S; Kuijpers M; Gijbels M; Schalkwijk C; Leitges M; Lawrence T; Touqui L; Plat J; Van Eck M; Rye K-A; De Winther M; Biessen E; Donners M, 2017, 'High density lipoproteins exert pro-inflammatory effects on macrophages via passive cholesterol depletion and PKC-NF-kB/STAT1-IRF1 signaling', Atherosclerosis, 263, pp. e6 - e6, http://dx.doi.org/10.1016/j.atherosclerosis.2017.06.046

Dinnes DLM; White MY; Kockx M; Traini M; Hsieh V; Kim MJ; Hou L; Jessup W; Rye KA; Thaysen-Andersen M; Cordwell SJ; Kritharides L, 2016, 'Human macrophage cathepsin B-mediated C-terminal cleavage of apolipoprotein A-I at Ser²²⁸ severely impairs antiatherogenic capacity', FASEB Journal, 30, pp. 4239 - 4255, http://dx.doi.org/10.1096/fj.201600508R

Cochran BJ; Hou L; Manavalan APC; Moore BM; Tabet F; Sultana A; Torres LC; Tang S; Shrestha S; Senanayake P; Patel M; Ryder WJ; Bongers A; Maraninchi M; Wasinger VC; Westerterp M; Tall AR; Barter PJ; Rye KA, 2016, 'Impact of perturbed pancreatic β-cell cholesterol homeostasis on adipose tissue and skeletal muscle metabolism', Diabetes, 65, pp. 3610 - 3620, http://dx.doi.org/10.2337/db16-0668

Gomes DJ; Velosa AP; Okuda LS; Fusco FB; da Silva KS; Pinto PR; Nakandakare ER; Correa-Giannella ML; Woods T; Brimble MA; Pickford R; Rye KA; Teodoro WR; Catanozi S; Passarelli M, 2016, 'Glycated albumin induces lipid infiltration in mice aorta independently of DM and RAS local modulation by inducing lipid peroxidation and inflammation', Journal of Diabetes and its Complications, 30, pp. 1614 - 1621, http://dx.doi.org/10.1016/j.jdiacomp.2016.07.001

Anastasius M; Kockx M; Jessup W; Sullivan D; Rye KA; Kritharides L, 2016, 'Cholesterol efflux capacity: An introduction for clinicians', American Heart Journal, 180, pp. 54 - 63, http://dx.doi.org/10.1016/j.ahj.2016.07.005

Cochran BJ; Ryder WJ; Parmar A; Tang S; Reilhac A; Arthur A; Charil A; Hamze H; Barter PJ; Kritharides L; Meikle SR; Gregoire MC; Rye KA, 2016, 'In vivo PET imaging with [¹⁸F]FDG to explain improved glucose uptake in an apolipoprotein A-I treated mouse model of diabetes', Diabetologia, 59, pp. 1977 - 1984, http://dx.doi.org/10.1007/s00125-016-3993-5

van der Vorst E; Theodorou K; Wu Y; Hoeksema M; Goossens P; Bursill C; Huitema L; Tas S; Gijbels M; McDaniels K; Wang CC; Leitges M; Lawrence T; Touqui L; Plat J; van Eck M; Rye KA; de Winther M; Biessen E; Donners M, 2016, 'LIPOPROTEINS AND LIPID METABOLISM: HDL. HIGH DENSITY LIPOPROTEINS EXERT PRO-INFLAMMATORY EFFECTS ON MACROPHAGES VIA PASSIVE CHOLESTEROL DEPLETION AND PKC-NF-KB/STAT1-IRF1 SIGNALING', ATHEROSCLEROSIS, 252, pp. E108 - E109, http://dx.doi.org/10.1016/j.atherosclerosis.2016.07.599

Geronimo FRB; Barter PJ; Rye KA; Heather AK; Shearston KD; Rodgers KJ, 2016, 'Plaque stabilizing effects of apolipoprotein A-IV', Atherosclerosis, 251, pp. 39 - 46, http://dx.doi.org/10.1016/j.atherosclerosis.2016.04.019

Van der Vorst EPC; Theodorou K; Hoeksema MA; Wu Y; Goossens P; Van Eck M; Rye K-A; De Winther MPJ; Biessen EAL; Donners MMP, 2016, 'High density lipoproteins exert pro-inflammatory effects on macrophages via passive cholesterol depletion and PKC-NF-kB/STAT1-IRF1 signaling', CARDIOVASCULAR RESEARCH, 111, pp. S10 - S10, http://dx.doi.org/10.1093/cvr/cvw123

Kockx M; Glaros E; Leung B; Ng TW; Berbée JFP; Deswaerte V; Nawara D; Quinn C; Rye KA; Jessup W; Rensen PCN; Meikle PJ; Kritharides L, 2016, 'Low-Density Lipoprotein Receptor-Dependent and Low-Density Lipoprotein Receptor-Independent Mechanisms of Cyclosporin A-Induced Dyslipidemia', Arteriosclerosis, Thrombosis, and Vascular Biology, 36, pp. 1338 - 1349, http://dx.doi.org/10.1161/ATVBAHA.115.307030

Siebel AL; Trinh SK; Formosa MF; Mundra PA; Natoli AK; Reddy-Luthmoodoo M; Huynh K; Khan AA; Carey AL; Van Hall G; Cobelli C; Dalla-Man C; Otvos JD; Rye KA; Johansson J; Gordon A; Wong NCW; Sviridov D; Barter P; Duffy SJ; Meikle PJ; Kingwell BA, 2016, 'Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial', Metabolism: Clinical and Experimental, 65, pp. 904 - 914, http://dx.doi.org/10.1016/j.metabol.2016.03.002

Kritharides L; Rye KA; Lambert TJ; Jessup W, 2016, 'Lipidology, cardiovascular risk, and schizophrenia', Current Opinion in Lipidology, 27, pp. 305 - 307, http://dx.doi.org/10.1097/MOL.0000000000000307

Barter PJ; Rye KA, 2016, 'Coronary artery disease: Scavenger receptor class B1-a target to reduce CHD risk?', Nature Reviews Cardiology, 13, pp. 249 - 250, http://dx.doi.org/10.1038/nrcardio.2016.50

Barter PJ; Rye KA, 2016, 'New era of lipid-lowering drugs', Pharmacological Reviews, 68, pp. 458 - 475, http://dx.doi.org/10.1124/pr.115.012203

Sultana A; Cochran BJ; Tabet F; Patel M; Cuesta Torres L; Barter PJ; Rye K, 2016, 'Inhibition of inflammatory signaling pathways in 3T3-L1 adipocytes by apolipoprotein A-I', The FASEB Journal

Julovi SM; Xue A; Thanh Le TN; Gill AJ; Bulanadi JC; Patel M; Waddington LJ; Rye KA; Moghaddam MJ; Smith RC, 2016, 'Apolipoprotein A-II plus lipid emulsion enhance cell growth via SR-B1 and target pancreatic cancer in vitro and in vivo', PLoS ONE, 11, http://dx.doi.org/10.1371/journal.pone.0151475

Barter PJ; Rye KA, 2016, 'Cholesteryl ester transfer protein inhibition is not yet dead - Pro', Arteriosclerosis, Thrombosis, and Vascular Biology, 36, pp. 439 - 441, http://dx.doi.org/10.1161/ATVBAHA.115.306879

Back to profile page